The Drivers Module shows relationships between Oramed Pharmaceuticals's most relevant fundamental drivers and provides multiple suggestions of what could possibly affect the performance of Oramed Pharmaceuticals over time as well as its relative position and ranking within its peers. Additionally take a look at Your Equity Center.
Oramed Pharmaceuticals Return On Equity vs. Current Ratio Fundamental Analysis
Oramed Pharmaceuticals is considered to be number one stock in current ratio category among related companies. It is rated below average in return on equity category among related companies . Current Ratio is calculated by dividing the Current Assets of a company by its Current Liabilities. It measures whether or not a company has enough cash or liquid assets to pay its current liability over the next fiscal year. The ratio is regarded as a test of liquidity for a company.
|Current Ratio ( times )|
|Return On Equity ( % )|
Typically, short-term creditors will prefer a high current ratio because it reduces their overall risk. However, investors may prefer a lower current ratio since they are more concerned about growing the business using assets of the company. Acceptable current ratios may vary from one sector to another, but generally accepted benchmark is to have current assets at least as twice as current liabilities (i.e. Current Ration of 2 to 1).Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how effecently a company utilizes investments to generate income.
For most industries Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.
Oramed Pharmaceuticals Return On Equity Comparison
Oramed Pharmaceuticals is currently under evaluation in return on equity category among related companies.